Study 35 of 38Orforglipron (LY-3502970) literatureJAMATop journal2026
Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment-Reply.
Not reported in abstract.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpus12
Preclinical · this one
8
Observational
1
Open-label
10
Randomised
7
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Orforglipron (LY-3502970) corpus
AEfficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.The lancet. Diabetes & endocrinology · 2026 · Mean percentage change in bodyweight was -5.9% with orforglipron 6 mg, -8.7% with 12 mg, and -7.9% with 36 mg, compared with -0.6% with placebo (all p<0.0001).HumanAEfficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m<sup>2</sup> and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.Obesity pillars · 2026 · n=260 · At Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.HumanDOrforglipron for Type 2 Diabetes and Pancreatic Risk Assessment.JAMA · 2026—DEstablishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.Lancet (London, England) · 2026—AQualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes.The patient · 2023 · n=60 · Patients reduced glycated hemoglobin by 1.6% (SD = 1.3) from a baseline of 8.3%.HumanACardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.Lancet (London, England) · 2026 · HR 0.84; 95% CI 0.59-1.20; p<0.0001 for non-inferiority.Human